hat
Nouvo konpayi-Editas medikaman, Crispr Thérapeutiques Et Thérapeutique Intellia-ont suspendue, licences Crispr teknoloji pou devlope somatiques sèlil modification pou nan klinik la. Aucun encore a ki maladi yo poursuit ak yon batay legal nan ki exactement jwi dwa Crispr teknoloji-. Men, Intellia ki yon afè ak famasetik Novartis gwo vize sou kansè Et enetik pwoblèm ant nan selil.
eng
New companies – Editas Medicine, Crispr Therapeutics and Intellia Therapeutics – have sprung up, licensing Crispr technology to develop somatic cell editing for the clinic. None have yet announced which diseases they are pursuing and a legal battle around who exactly owns the rights to Crispr technology rages. But Intellia has a deal with pharmaceutical giant Novartis to focus on cancer and genetic disorders arising in blood cells.